Determination and allelic allocation of seven nucleotide transitions within the arylamine N-acetyltransferase gene in the Polish population

Clinical Pharmacology and Therapeutics

Volumn 59, Issue 4, 1996, Pages 376-382

  Mrozikiewicz, Przemyslaw M ^a   Cascorbi, Ingolf ^a   Brockmöller, Jürgen ^a   Roots, Ivar ^a,b  

^a HUMBOLDT UNIVERSITY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE;

ACETYLATOR PHENOTYPE; ADOLESCENT; ADULT; ALLELE; ARTICLE; CHILD; DNA SEQUENCE; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATION; POLAND; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADOLESCENT; ALLELES; ARYLAMINE N-ACETYLTRANSFERASE; BASE SEQUENCE; CHILD; CHILD, PRESCHOOL; FEMALE; GENOTYPE; HUMANS; MALE; MOLECULAR SEQUENCE DATA; NUCLEOTIDES; POINT MUTATION; POLAND; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH;

EID: 0029927489     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90104-6     Document Type: Article

References (24)

1. Evans DAP. N-Acetyltransferase. In: Kalow W, ed. Pharmacogenetics of drug metabolism. New York: Pergamon Press, 1992:95-178.
2. Roots I, Drakoulis N, Brockmöller J. Polymorphic enzymes and cancer risk: concepts, methodology and data review. In: Kalow W, ed. Pharmacogenetics of drug metabolism. New York: Pergamon Press, 1992:815-41.
3. Brockmöller J, Roots I. Assessment of liver metabolic function - clinical implications. Clin Pharmacokinet 1994;27:216-48.
4. Grant DM, Blum M, Demierre A, Meyer UA. Nucleotide sequence of an intronless gene for a human arylamine N-acetyltransferase related to polymorphic drug acetylation. Nucleic Acids Res 1989;17:3978.
5. Vatsis KP, Weber WW, Bell DA, et al. Nomenclature for N-acetyltransferases. Pharmacogenetics 1995;5:1-17.
6. Blum M, Demierre A, Grant DM, Heim M, Meyer UA. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci USA 1991;88:5237-41.
7. Vatsis KP, Martell KJ, Weber WW. Diverse point mutations in the human gene for polymorphic N-acetyltransferase. Proc Natl Acad Sci USA 1991;88: 6333-7.
8. Ohsako S, Deguchi T. Cloning and expression of cDNAs for polymorphic and monomorphic arylamine N-acetyltransferases from human liver. J Biol Chem 1990;265:4630-4.
9. Bell DA, Taylor JA, Butler MA, et al. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis 1993;14:1689-92.
10. Cascorbi I, Drakoulis N, Brockmöller J, Maurer A, Sperling K, Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 1995;57:581-92.
11. Grant DM. Molecular genetics of the N-acetyltransferases. Pharmacogenetics 1993;3:45-50.
12. Lin HJ, Han CY, Lin BK, Hardy S. Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, blacks, Hispanics, and whites: application to metabolic epidemiology. Am J Hum Genet 1993;52:827-34.
13. Lin HJ, Han CY, Lin BK, Hardy S. Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics 1994;4:125-34.
14. Agúndez JA, Martínez C, Olivera M, Ledesma MC, Ladero JM, Benítez J. Molecular analysis of the arylamine N-acetyltransferase polymorphism in a Spanish population. CLIN PHARMACOL THER 1994;56:202-9.
15. Agúndez JA, Ladero JM. Olivera M, Abildúa R, Roman JM, Benítez J. Genetic analysis of the arylamine N-acetyltransferase polymorphism in breast cancer patients. Oncology 1995;52:7-11.
16. Mrozikiewicz PM, Drakoulis N, Roots I. Polymorphic arylamine N-acetyltransferase (NAT2) genes in children with insulin-dependent diabetes mellitus. CLIN PHARMACOL THER 1994;56:626-34.
17. Graf T, Broly F, Hoffmann F, Probst M, Meyer UA, Howald H. Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA tests in healthy human volunteers. Eur J Clin Pharmacol 1992;43:399-403.
18. Rothman N, Hayes RB, Bi W, et al. Correlation between N-acetyltransferase activity and NAT2 genotype in Chinese males. Pharmacogenetics 1993;3:250-5.
19. Cascorbi I, Brockmöller J, Bauer S, Reum T, Roots I. NAT2*12A (803A→G) codes for rapid arylamine N-acetylation in humans. Pharmacogenetics [In press].
20. Vatsis KP, Weber WW. Structural heterogeneity of Caucasian N-acetyltransferase at the NAT1 gene locus. Arch Biochem Biophys 1993;301:71-6.
21. Hein DW, Ferguson RJ, Doll MA, Rustan TD, Gray K. Molecular genetics of human polymorphic arylamine N-acetyltransferase: enzymatic analysis of 15 recombinant wild type, mutant and chimeric NAT2 allozymes. Hum Mol Genet 1994;3:729-34.
22. Mashimo M, Suzuki T, Abe M, Deguchi T. Molecular genoryping of N-acetylation polymorphism to predict phenotype. Hum Genet 1992;90:139-43.
23. Dróżdż M, Gierek T, Jendryczko A, Pilch J, Piekarska J. N-Acetyltransferase phenotype of patients with cancer of the larynx. Neoplasma 1987;34:481-4.
24. Stryjek-Kamińska D, Malczewski B, Kopeć A, Rowińska-Marcińska K. Acetylator phenotypes in diabetes mellitus. Acta Diabetol Lat 1988;25:41-8.